Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

More than half of depression patients give up their treatment

23.11.2010
Most patients who take anti-depressants give up their treatment in less than six months, the minimum period recommended for treating severe depression and other derived pathologies. This is the conclusion of a new study carried out by Catalan researchers, which reveals that only 25% continue their treatment for more than 11 months.

"Only one in every five patients properly completes their treatment", Catalina Serna, co-author of the study, and an expert at the Jordi Gol Primary Care Research Institute (IDIAP) in Lleida, tells SINC.

From 2003 to 2007, researchers from the Catalan Institute of Health (ICS) and the IDIAP Jordi Gol analysed 7,525 patients who were starting anti-depression treatment, looking at how long they continued with this treatment and the reasons why they gave it up.

The results, published this year in the journal European Psychiatry, pointed out that, of the 3.2% of the population who started treatment for depression, 56% stopped taking their medication during the first four months, and less than 25% of the cohort continued their treatment for more than 11 months.

The researchers say patients are most likely to give up their medication during the acute stage of depression (the first months). "The levels to which they stick to their treatment also declines steeply between the first four and 12 months of the monitoring period", Serna points out.

"In our study, only 22% of patients completed their treatment", the expert explains. "The higher completion rates seen in chronic cases are in multiply-medicated patients, who are twice as likely as other patients to continue with their treatment for depression (31% vs. 15.3%).

Men are more likely to give up treatment

Meanwhile, men are more at risk of giving up their treatment earlier than women (50% of men gave up their medication after two months, while 50% of women gave it up after three months).

Depression is one of the commonest psychiatric diseases among adults, above all in industrialised countries. A European study carried out in 2004 found that almost 13% of individuals surveyed reported having a serious depressive illness at some point in their lives. This study revealed that in Spain, where anti-depressant use has risen in line with the availability of new drugs, 10.5% of the population suffers from depression.

References:

M. Catalina Serna, Inés Cruz, Jordi Real, Eduardo Gascó, Leonardo Galván. "Duration and adherence of anti-depressant treatment (2003 to 2007) based on prescription data base". European Psychiatry , 25 (2010) 206-213, mayo de 2010.

Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. "Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project." Acta Psychiatr Scand Suppl 2004

SINC | EurekAlert!
Further information:
http://wwwplataformasinc.es

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>